Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial.

Given the generally solid safety profile of Eylea and this higher-dose version, we expect Regeneron and partner Bayer to gain approval in late 2023/early 2024 for this new formulation.

Marketing Regeneron's Eylea still sitting pretty even after new data from would-be rivals Roche, Novartis: analyst By Carly Helfand Feb 12, 2018 10:27am macular edema VEGF Eylea Lucentis ...

With the FDA’s approval of Yesafili and Opuviz, the price tag for the treatment will also get a disruption. Currently, paying for Eylea out of pocket can cost patients $1,958 per 0.05 milliliters.

Based on its bullish expectation, Regeneron raised its forecast for 2013 Eylea sales. Regeneron now expects 2013 sales of Eylea in the range of $1.35-$1.375 billion (old guidance: $1.3-$1.35 billion).